Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.6994
+0.0094 (1.36%)
Oct 30, 2025, 4:00 PM EDT - Market closed
Cue Biopharma Stock Forecast
Stock Price Forecast
The 2 analysts that cover Cue Biopharma stock have a consensus rating of "Strong Buy" and an average price target of $3.00, which forecasts a 328.94% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $4.00.
Price Target: $3.00 (+328.94%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 25, 2025.
Analyst Ratings
The average analyst rating for Cue Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +471.92% | Aug 25, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $2 | Buy | Reiterates | $2 | +185.96% | Apr 2, 2025 |
| Stifel | Stifel | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +471.92% | Aug 20, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $15 → $2 | Buy | Maintains | $15 → $2 | +185.96% | Jul 26, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $3 | Buy | Maintains | $8 → $3 | +328.94% | Jul 26, 2024 |
Financial Forecast
Revenue This Year
7.45M
from 9.29M
Decreased by -19.76%
Revenue Next Year
6.72M
from 7.45M
Decreased by -9.82%
EPS This Year
-0.43
from -0.72
EPS Next Year
-0.45
from -0.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.8M | 10.5M | |||
| Avg | 7.5M | 6.7M | |||
| Low | 5.3M | 980,000 |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.0% | 40.9% | |||
| Avg | -19.8% | -9.8% | |||
| Low | -43.0% | -86.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.40 | -0.32 | |||
| Avg | -0.43 | -0.45 | |||
| Low | -0.45 | -0.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.